Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cannabidiol - GW Pharmaceuticals

Drug Profile

Cannabidiol - GW Pharmaceuticals

Alternative Names: CBD - GW Pharmaceuticals; Epidiolex; Epidyolex; GW-42003; GWP-42003; GWP-42003-P

Latest Information Update: 31 Aug 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GW Pharmaceuticals
  • Developer GW Pharmaceuticals; University of Alabama at Birmingham; University of Utah
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiacnes; Antibacterials; Antiepileptic drugs; Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antiparkinsonians; Antipsoriatics; Antipsychotics; Antirheumatics; Anxiolytics; Cannabinoids; Cardiovascular therapies; Cyclohexenes; Drug withdrawal therapies; Heart failure therapies; Hepatoprotectants; Muscle relaxants; Neuroprotectants; Obesity therapies; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Cannabinoid receptor CB1 inverse agonists; Cannabinoid receptor CB2 inverse agonists; Serotonin 1 receptor modulators; Transient receptor potential channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Lennox-Gastaut syndrome; Dravet syndrome; Cerebral ischaemia; Infantile spasms; Tuberous sclerosis
  • New Molecular Entity No

Highest Development Phases

  • Marketed Dravet syndrome; Lennox-Gastaut syndrome; Tuberous sclerosis
  • Phase III Epilepsy; Infantile spasms; Rett syndrome
  • Phase II Heroin-related disorders; Opioid-related disorders; Parkinson's disease; Pervasive child development disorders; Schizophrenia
  • Phase I Cerebral ischaemia
  • No development reported Duchenne muscular dystrophy; Ovarian cancer
  • Discontinued Dyslipidaemias; Non-alcoholic fatty liver disease; Type 2 diabetes mellitus; Ulcerative colitis

Most Recent Events

  • 10 Aug 2021 UK MHRA approves cannabidiol as an adjunctive treatment for associated seizures in Tuberous sclerosis complex in August 2021
  • 09 Aug 2021 GW Research terminates the phase III ARCH trial in Rett syndrome (In children, In adults, In adolescents) in United Kingdom, USA, Spain, Italy, Canada and Australia due to COVID-19 pandemic and recruitment challenges in parent study (PO) (NCT04252586) EudraCT2019-001605-24)
  • 03 Aug 2021 Jazz Pharmaceuticals plans pivotal phase III trials for Epilepsy in the first half of 2022
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top